Dulaglutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
An injectable GLP-1 receptor agonist for type 2 diabetes, also used off-label for weight loss. Unlike many peptides here, the case rests on large human trials, not animal or mechanism data: solid evidence for HbA1c reduction, weight loss, and cardiovascular risk reduction, with low hypoglycemia risk. Main concerns are common GI side effects and a theoretical, boxed-warning risk of thyroid tumors in rodents. FDA-approved (Trulicity), prescription-only.
Read Full recordStudied uses & evidence
Studied uses(6)
Glycemic control (HbA1c reduction)
HighLarge randomized trials show dose-dependent HbA1c reductions of about 1.5 to 1.9 percent.
Cardiovascular risk reduction
HighDedicated cardiovascular trial showed modest risk reduction, driven mainly by fewer strokes.
Weight loss
HighHuman trials show modest weight loss, about 3 to 5 kg, not FDA-approved for weight management.
Evidence limits
- Evidence Level
- Level 1 — Strong
Dulaglutide has strong cardiovascular outcomes evidence from REWIND (N=9,901; median follow-up 5.4 years), a large GLP-1 receptor agonist cardiovascular outcomes trial with long follow-up. The AWARD program includes 11+ phase III RCTs demonstrating consistent glycemic efficacy across monotherapy and combination therapy settings. Head-to-head trials have shown superiority over metformin, sitagliptin, and exenatide, and non-inferiority to liraglutide and insulin glargine.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of MTC
AbsoluteFDA boxed warning for thyroid C-cell tumor risk. Contraindicated in MTC/MEN2.
History of pancreatitis
HighMonitor for and discontinue if pancreatitis occurs. Acute pancreatitis reported in trials.
Severe gastroparesis
HighGLP-1 agonist slows gastric emptying. Avoid with severe gastroparesis.
Severe renal impairment
ModerateGI-related dehydration may worsen renal function. Monitor closely.
General cautions
Pregnancy
AbsolutePregnancy — precaution, not an absolute FDA contraindication. Animal studies suggest fetal risk; use during pregnancy only if the potential benefit justifies that risk.
Risk summary(8)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events
HighHypoglycemia (when combined with insulin or sulfonylureas)
HighGallbladder disease
ModeratePancreatitis
LowAcute kidney injury
LowSerious hypersensitivity reactions
LowCardiac conduction abnormalities
LowThyroid C-cell tumors (boxed warning)
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.